Opdivo (nivolumab) is a new cancer treatment, referred to as immunotherapy, that stimulates the patient’s immune system to the cancer.
Opdivo is showing promise as a treatment that is helping people live longer without the cancer growing and live longer overall than if they did not take Opdivo or took other cancer medicines instead.
Opdivo is currently approved by the FDA for the treatment of various cancers, including lung, melanoma, kidney cancers (renal cell carcinoma) and the blood cancer Hodgkin lymphoma.
It is also being studied for the treatment of many other cancer types.
How it Works
This cancer drug goes by the trade name Opdivo, it’s generic name is nivolumab
Developed by Bristol-Myers Squibb, Opdivo is a new type of cancer treatment called immunotherapy. It is a immune checkpoint inhibitor, which, basically, helps to activate the immune system from being dormant. These “check points” also prevent the normal immune system from attacking everything, such as many types of normal cells.